Compare Grand House Mulia Tbk. (HOMI) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grand House Mulia Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Grand House Mulia Tbk. trades at Rp232 (market cap 384.3B, 3.49M 24h volume), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Grand House Mulia Tbk. is far larger — about 3.7× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| HOMI | SCPI | |
|---|---|---|
Market Cap | 384.3B | 104.4B |
Volume | 3.49M | — |
Lot | 34.89K | — |
Turnover | 796.11M | — |
Average Price | 228.18 | — |
Value | 796.11M | — |
Indicative Equilibrium Price | 232 | — |
Indicative Equilibrium Volume | 110 | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grand House Mulia Tbk.
PT Grand House Mulia, Tbk (“the Company”) was established in Republic of Indonesia based on the Notarial Deed No. 1 dated January 9, 2006 of Suryati Moerwibowo, S.H., The Company has commercially operated in April 2019.
Read more on HOMI →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
